The AACR and the cancer research community benefit from collaborations with many oncology stakeholders and more than 100 cancer organizations around the world. “We share our passion to change the face of cancer and our belief that we are made stronger by working together,” said AACR CEO Margaret Foti, PhD, MD (hc).

Annual Meeting Program Committee Chair Robert H. Vonderheide, MD, DPhil, shares a few highlights from Monday’s schedule to help you plan your day.

Sotorasib and adagrasib, the first agents to directly target mutant KRAS cancers, became overnight sensations when they were approved in 2021 and 2022, respectively. Four researchers, including Dafna Bar-Sagi, PhD, described the decades of research that led to the approvals during the first plenary session at the Annual Meeting. They also described ongoing research efforts…

AACR Past President Elizabeth M. Jaffee, MD, FAACR, recipient of the AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research, will discuss her personal journey in cancer research during her award lecture Monday afternoon.

Among other topics, the session’s speakers will discuss evolving concerns in the current medical and sociopolitical environment, particularly when patient survival is compromised when therapies are deferred or omitted to prevent fetal exposure, according to AACR President Lisa M. Coussens, PhD, FAACR.

The Annual Meeting program features five forum sessions Monday evening on a range of topics, from adolescent and young adult cancers, CAR cells, and data-sharing, to taking cancer care out of the hospital and into the home.